Dosimetry of fractionated experimental radioimmunotargeting with idiotypic and anti-idiotypic anticytokeratin antibodies

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2681-2688

  Norrlund, Rauni Rossi ^a   Ullén, Anders ^a   Sandström, Per ^a   Holback, Daniel ^a   Johansson, Lennart ^a   Stigbrand, Torgny ^a   Hietala, Sven Ola ^a   Åhlström, Katrine Riklund ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti idiotype; Dosimetry; Fractionated; HeLa Hep2; Iodine 125; Monoclonal antibody; Radioimmunotargeting

Indexed keywords

CYTOKERATIN; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN IDIOTYPE; MONOCLONAL ANTIBODY I 125;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DOSIMETRY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION; TUMOR XENOGRAFT;

EID: 2642620545     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2681::aid-cncr46>3.0.co;2-5     Document Type: Conference Paper

References (38)

1. Goldenberg D. Cancer radioimmunotherapy: passing through adolescense. Tumor Targeting 1995;1:233-5.
2. Blumenthal R, Sharkey R, Goldenberg D. Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony stimulating factor intervention to reduce myelosuppression. J Natl Cancer Inst 1992;84:399-407.
3. Blumenthal R, Sharkey R, Goldenberg D. Overcoming dose-limiting, radioantibody-induced myelotoxicity. In: Goldenber D, editor. Cancer therapy with radiolabeled antibodies. Boca Raton, FL: CRC Press, 1995;295-314.
4. Norrgren K, Strand S-E, Nilsson R, Lindgren L, Sjögren H-O. A general, extracorporeal immunoadsorption method to increase the tumor-to-nontumor tissue ratio in radioimmunotargeting and radioimmunotherapy. J Nucl Med 1993;34:448-54.
5. Norrgren K, Strand SE, Nilsson R, Lindgren L, Lilliehorn P. Evaluation of extracorporeal immunoadsorption for reduction of the blood background in diagnostic and therapeutic applications of radiolabeled monoclonal antibodies. Anti-body Immunoconj Radiopharm 1991;4:907-14.
6. Lear J, Kasliwal R, Feyerabend A, Pratt J, Bunn P, Dienhart D, et al. Improved tumor imaging with radiolabeled monoclonal antibodies by plasma clearance of unbound antibody with anti-antibody column. Radiology 1991;179:509-12.
7. Sharkey R, Boerman O, Natale A, Pawlyk D, Monestier M, Losman J, et al. Enhanced clearance of radiolabeled murine monoclonal antibody by a syngeneic anti-idiotype antibody in tumor bearing nude mice. Int J Cancer 1992;51:266-73.
8. Ullén A, Sandström P, Riklund Åhlström K, Sundström B, Nilsson B, Ärlestig L, et al. Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumor:nontumor ratio in experimental radioimmunolocalization. Cancer Res 1995;55:5868-87.
9. Buchegger F, Rojas A, Delaloye AB, Vogel CA, Mirimanoff RO, Coucke P, et al. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Cancer Res 1995;55:83-9.
10. Kalofonos H, Rowlinson G, Epenetos AA. Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation. Cancer Res 1990;50:159-63.
11. Kuhn J, Beatty B, Wong J, Esteban J, Wanek F, Buras R, et al. Interferon enhancement of radioimmunotherapy for colon carcinoma. Cancer Res 1995;51:2335-9.
12. Nieroda C, Milenic D, Carrasquillo J, Schlom J, Greiner J. Improved tumour radioimmunodetection using a single chain Fv and γ-interferon: potential clinical applications for radioimmunoguided surgery and γ scanning. Cancer Res 1995;55:2858-65.
13. Paganelli G, Malcovati M, Fazio F. Monoclonal antibody pre-targeting techniques for tumor localization: the avidin-biotin system. Nucl Med Commun 1991;12:211-34.
14. Magnani P, Paganelli G, Modorati G, Zito F, Songini C, Sudati F, et al. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 1996;37:967-71.
15. Murray JL. Radioimmunotherapy of colorectal cancer. In: Goldenberg DM, editor. Cancer therapy with radiolabeled antibodies. Boca Raton, FL: CRC Press, 1995:173-87.
16. Moll R, Franke W, Schiller D. The catalogue of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
17. Sundström B, Johansson B, Hietala S-O, Stigbrand T. Radioimmunolocalzation in nude mice using anticytokeratin monoconal antibodies.Tumor Biol 1990;11:158-66.
18. Quinlan RA, Schiller DL, Hatzfeld M, Achtstätter T, Moll R, Jorcano J, et al. Patterns of expression and organization of cytokeratin in intermediate filaments. Ann N Y Acad Sci 1985;455:282-306.
19. Sundström B, Nathrath W, Stigbrand T. Diversity in immunoreactivity of tumor-derived cytokeratin monoclonal antibodies. J Histochem Cytochem 1989;37:1845-54.
20. Franke WW, Winter S, Schmid E, Söllner P, Hämmerling G, Achstätter T. Monoclonal cytokeratin antibody recognizing a heterotypic complex: immunological probing of conformational states of cytoskeletal proteins in filaments and in solution. Exp Cell Res 1987;73:17-37.
21. Ellet WH, Humes RM. Absorbed fractions for small volumes containing photoemitting radioactivity. MIRD Pamphlet No 8. J Nucl Med 1971;5(Suppl):25-32.
22. Carlsson G, Gullberg B, Hafström L. Estimation of liver tumor volume using different formulas: an experimental study in rats. J Cancer Res Clin Oncol 1983;105:20-3.
23. Riklund Åhlström K, Ullén A, Makiya R, Sundström B, Thornell L-E, Stigbrand T. Radioimmunotherapy of HeLa cell tumours in nude mice by combination of iodine-131-labelled monoclonal antibodies against placental alkaline phosphatase and cytokeratin. Tumor Targeting 1995;1:239-44.
24. Carlsson L, Sottrup-Jensen L, Stigbrand T. A two-site monoclonal enzyme assay for pregnancy-associated alfa2 glycoprotein. J Immunol Methods 1987;104:73-9.
25. 131I-labeled human growth hormone of high specific radioactivity. J Biochem (Tokyo) 1963;89:114-23.
26. Goodwin DA. Pharmacokinetics and antibodies. J Nucl Med 1988;28:1358-62.
27. Stigbrand T, Hietala S-O, Johansson B, Makiya R, Riklund K, Ekelund L. Tumor radioimmunolocalization in nude mice by use of antiplacental alkaline phosphates monoclonal antibodies. Tumor Biol 1989;10:243-51.
28. Vogel CA, Bischof-Delaloye A, Mach JP, Pelegrin A, Hardman N, Delaloye B, et al. Direct comparison of a radioiodinated intact chimeric anti-CEA Mab with its F(ab)′2 fragment in nude mice bearing different human colon cancer xenografts. Br J Cancer 1993;68:684-90.
29. 2 fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts. Int J Cancer 1988;42:368-72.
30. 2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Res 1989;49:3095-103.
31. Molthoff CFM, Pinedo HM, Schlüper HMM, Nijman HW, Boven E. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab)′2 fragments in experimental ovarian cancer. Br J Cancer 1992;65:677-83.
32. 125I-labeled anticytokeratin and anti-PLAP monoclonal antibodies. Anticancer Res 1991;11:555-60.
33. Blumentahl RD, Kashi R, Stephens R, Sharkey RM, Goldenberg DM. Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p. Cancer Immunol Immunother 1991;32:303-10.
34. Constine L, Rubin P. Total body irradiation: normal tissue effects. In: Bleehen N, editor. Radiobiology in radiotherapy. Dorchester: Springer-Verlag, 1988;95-121.
35. 131I-Lym-1. Cancer Res 1990;50(Suppl 3):1014-6.
36. Schlom J, Molino A, Simpson J, Siler K, Roselli M, Hinkle G, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 1990;82:763-71.
37. Schlom J, Siler K, Milenic D, Eggensperger D, Colcher D, Miller L, et al. Monoclonal antibody-based therapy of a human tumour xenograft with a lutetium-177-labeled immunoconjugate. Cancer Res 1991;51:2889-96.
38. 131I-labeled monoclonal antibody CC49. Cancer Res 1995;55(Suppl):5881-7.